NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues rose 5 percent, and it swung from a loss to a profit.

The San Diego-based firm missed analysts' consensus estimate, and its shares plunged 21 percent to $32.99 in after-hours trade — though its shares were trading at $35.23 in early Wednesday trade. The shortfall was due to a few issues, including a quality control issue related to sequencing reagent kits that could impact Illumina's Q4 revenues as well.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.